Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy Male Subjects. A Randomised, Doubleblind, Placebo-controlled, Monocentre, First-In-Human Study.

Trial Profile

Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy Male Subjects. A Randomised, Doubleblind, Placebo-controlled, Monocentre, First-In-Human Study.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs MRG-110 (Primary)
  • Indications Heart failure; Ischaemia
  • Focus Adverse reactions; First in man
  • Sponsors Servier
  • Most Recent Events

    • 27 Mar 2018 Status changed from planning to recruiting, according to a miRagen Therapeutics media release.
    • 15 Nov 2017 New trial record
    • 08 Nov 2017 According to a miRagen Therapeutics media release, trial initiation is anticipated in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top